Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Wada

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Blood|August 13, 2009
Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cellsRyan A Wilcox, David A Wada, Steven C Ziesmer, et al.
Blood|July 15, 2009
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disordersRyan A Wilcox, Andrew L Feldman, David A Wada, et al.
Cancer Medicine|March 7, 2025
Mental Health Diagnoses in Patients With Mycosis Fungoides and Potential Impact on Oncologic OutcomesJackson N Howell, Bayarmaa Mark, David A Wada, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 21, 2010
Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsiesDavid A Wada, Mark E Law, Eric D Hsi, et al.
Blood|February 6, 2014
GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical featuresTianjiao Wang, Andrew L Feldman, David A Wada, et al.
Blood|August 25, 2021
Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathwayKatie Lee, Mark G Evans, Lei Yang, et al.
JAMA Surgery|October 22, 2025
Gene Expression Profile-Based Test to Predict Melanoma Sentinel Node Status: The MERLIN_001 StudyTina J Hieken, Michael E Egger, Christina V Angeles, et al.
Journal of the American Academy of Dermatology|February 14, 2026
Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER studyFrank Siebenhaar, Sigurd Broesby-Olsen, Mariana Castells, et al.
Nature Medicine|August 26, 2025
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Nature Cancer|January 29, 2026
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Blood|August 13, 2009
Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cellsRyan A Wilcox, David A Wada, Steven C Ziesmer, et al.
Blood|July 15, 2009
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disordersRyan A Wilcox, Andrew L Feldman, David A Wada, et al.
Cancer Medicine|March 7, 2025
Mental Health Diagnoses in Patients With Mycosis Fungoides and Potential Impact on Oncologic OutcomesJackson N Howell, Bayarmaa Mark, David A Wada, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 21, 2010
Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsiesDavid A Wada, Mark E Law, Eric D Hsi, et al.
Blood|February 6, 2014
GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical featuresTianjiao Wang, Andrew L Feldman, David A Wada, et al.
Blood|August 25, 2021
Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathwayKatie Lee, Mark G Evans, Lei Yang, et al.
JAMA Surgery|October 22, 2025
Gene Expression Profile-Based Test to Predict Melanoma Sentinel Node Status: The MERLIN_001 StudyTina J Hieken, Michael E Egger, Christina V Angeles, et al.
Journal of the American Academy of Dermatology|February 14, 2026
Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER studyFrank Siebenhaar, Sigurd Broesby-Olsen, Mariana Castells, et al.
Nature Medicine|August 26, 2025
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Nature Cancer|January 29, 2026
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Pageof 6